TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03496688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation
Study: NCT04447586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer
Description: Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure measurement during exhalation through an alternative PEP device/soft drink straw.
Description: Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets.
Study: NCT03496688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation
Study: NCT01251588

Intervention type: BIOLOGICAL
Intervention: autologous cultured chondrocytes on porcine collagen membrane
Description: Implantation received in the previous MACI00206 study

Intervention type: PROCEDURE
Intervention: Microfracture
Description: Arthroscopic Microfracture treatment received in the previous MACI00206 study
Study: NCT04563091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis with online HFR
Description: 1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment.
Study: NCT03034785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexiMitt
Description: The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexiMitt
Description: The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
Study: NCT04413084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze stability exercises
Description: Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff Exercises
Description: Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center.
Study: NCT01998451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Tauroursodeoxycholic acid
Description: patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
Study: NCT01750580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT04614688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education Platform
Description: The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
Study: NCT03239626

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: POHIM-RT
Description: postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
Study: NCT01370031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenil® Modulite® via Volumatic™ spacer
Description: Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenil® Modulite® via AeroChamber Plus™ plus charcoal block
Description: Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
Description: Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
Study: NCT02636517

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
Study: NCT03712878

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV
Study: NCT01025089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Description: Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
Study: NCT02514889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-counting
Description: The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlate
Description: The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls.
Study: NCT00740116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
Study: NCT02153983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6Mg Cap
Description: Colchicine 0.6 mg given twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules given
Description: Placebo capsules given twice daily
Study: NCT01922869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Study: NCT01286025

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video case modality
Description: Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text case modality
Description: Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
Study: NCT03757936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
Study: NCT04870294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teeth treated with composite resin, control group
Description: The teeth grouped in group R were treated with composite resin restoration without liner material.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration
Description: The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
Study: NCT03350503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Toric A-code IOL
Description: Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Removal of cataractous lens and implantation of IOL
Study: NCT01757119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tardyferon 80 mg
Description: Oral administration (2 tablets)
Study: NCT00016952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT00834912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study: NCT02153983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6Mg Tab
Description: Open-label colchicine
Study: NCT01596790

Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis by EPISPOT and Cellsearch
Description: For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
Study: NCT01397409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.
Study: NCT02489097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
Study: NCT02253004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Single oral administration of active or placebo one week apart
Study: NCT01397409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.
Study: NCT03240588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System
Description: Spinal cord stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System
Description: Spinal cord stimulation
Study: NCT03240588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System
Description: Spinal cord stimulation
Study: NCT01063465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early weightbearing
Description: Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early weightbearing
Description: Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
Study: NCT01397409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-150998
Description: AGN-150998 Intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg given by intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg given by intravitreal injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection
Description: Stage 3: Sham injection at Weeks 12 and 16.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection
Description: Stage 3: Sham injection at Weeks 12 and 16.
Study: NCT01866891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three months of regular perdialytic physical activity (cycling)
Description: Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
Study: NCT05021159

Intervention type: OTHER
Intervention: MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)
Description: the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
Study: NCT00507312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD medical device (ViScope)
Description: Device
Study: NCT03909074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 36-71 months old children-experimental EV71 vaccine.
Description: Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
Study: NCT00507312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD medical device (ViScope)
Description: Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD medical device (ViScope)
Description: Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSIRO device
Description: device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSIRO device
Description: device
Study: NCT02253004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03694756

Intervention type: DEVICE
Group type: OTHER
Intervention: TMEM-MRI
Description: TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.

Intervention type: DEVICE
Group type: OTHER
Intervention: TMEM-MRI
Description: TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.

Intervention type: DEVICE
Group type: OTHER
Intervention: TMEM-MRI
Description: TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA
Description: FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
Study: NCT03425929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal administration, 24 international units (IU) oxytocin.
Study: NCT02753361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: In the second arm, ultrasound will be used to guide the regional block
Study: NCT05646459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
Study: NCT00507312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSIRO device
Description: device
Study: NCT02793024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
Study: NCT03425929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal administration, 24 international units (IU) oxytocin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study: NCT05646459

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: floss
Description: This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: proxabrush
Description: This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
Study: NCT02500043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.